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1. Introduction  
Neurofibromatosis type 1 [Nf-1, OMIM #1622001], formerly known as von Recklinghausen 
disease, is one of the most frequent disorders affecting mankind, inherited as an autosomal 
dominant trait. The relatively high prevalence, with an incidence at birth of approximately 
one in 2500 to 3500 live births, and a progressive nature of the disorder, notable for its 
phenotypic variability with almost 100% penetrance, as well as high proportion of sporadic 
cases (almost 50% of de novo mutations), constitute for the clinical magnitude of this 
disease. Multiple café au lait spots [CALs], axillary and inguinal freckling, multiple discrete 
cutaneous neurofibromas [NFM] and more prominent plexiform neurofibromas [PNF], and 
iris Lisch nodules constituted for the cardinal signs of the disease. Learning disabilities and 
attention deficits states, but usually with normal intelligence in adulthood, are present in at 
least 50% of individuals with Nf-1. Neurofibromatosis type 1 belongs to the group of 
disorders with significantly increased risk of tumorigenesis. The other significant 
manifestations of Nf-1 include bone dysplasias, clinically presented as progressive 
dystrophic scoliosis, vertebral dysplasia, overgrowth and tibial dysplasia with 
pseudarthrosis, and vasculopathy. Pubertal development is usually normal, but precocious 
puberty, especially in those with an optic chiasm glioma, as well as delayed puberty, may 
commonly occur in children with Nf-1. The life expectancy of Nf-1 patients is assumed to be 
reduced by 15 years. The most important causes of early death in these patients are 
malignant peripheral nerve sheath tumors and severe complications of vasculopathy 
(Friedman et al., 1999; Jett & Friedman, 2010; Larizza et al., 2009). 
Despite the possibility of molecular testing, the diagnosis of Nf-1 is still based on clinical 
findings and is usually unequivocal in all but the young children (DeBella et al., 2000b). The 
diagnostic criteria for Nf-1 (Tabl. 1) were developed by the US National Institutes of Health 
(National Institute of Health [NIH], 1988) and are generally accepted worldwide for routine 
clinical use (Ferner et al., 2007; Williams et al., 2009). The disease is characterizes by extreme 
clinical variability, not only between unrelated, but also among affected individuals within a 
                                                                 
1 Online Mendelian Inheritance in Man, OMIM (TM). Johns Hopkins University, Baltimore, MD. MIM 
Number: #162200, 07/06/2011. World Wide Web URL: http://www.ncbi.nlm.nih.gov/omim/ 
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single family carrying the same type of mutation, and even within a single person with Nf-1 
at different times in life. Penetrance of NF1 gene mutation is virtually complete (100% of 
penetration) after childhood and the frequency of more serious complications increases with 
age. Various manifestations of Nf-1 have different characteristic times of appearance 
(DeBella et al., 2000b; Boulanger & Larbrisseau, 2005; Friedman ed., 1999; Williams et al., 
2009). The clinical NIH diagnostic criteria are both highly specific and highly sensitive only 
in adults. Less than half of youngest children with no family history of Nf-1 meet NIH 
criteria,  although almost all do by adolescence. Yet, neonates who inherited NF1 mutation 
from one of the parents can usually be identified within the first year of life by the presence 
of numerous CALs (DeBella et al., 2000b). 
 
The presence of two or more of the following features is required for the diagnosis of Nf-1: 
1. Six or more café au lait macules over 5 mm in greatest diameter in prepubertal 
individuals and over 15 mm in greatest diameter in postpubertal individuals 
2. Two or more neurofibromas of any type, or one plexiform neurofibroma 
3. Freckling in the axillary or inguinal regions 
4. Optic glioma 
5. Two or more Lisch nodules (iris hamartomas) 
6. A distinctive osseous lesion such as sphenoid dysplasia or tibial pseudarthrosis 
7. A first-degree relative (parent, sib, or offspring) with Nf-1 as defined by the above 
criteria 
Table 1. The NIH diagnostic criteria for neurofibromatosis type 1 
Neurofibromatosis type 1 is caused by heterozygous mutations (intragenic or microdeletion) 
in NF1 tumor suppressor gene, located at 17q11.2. Its product, neurofibromin, has different 
biochemical interactions, including association to microtubules and participation in several 
signaling pathways, especially as a member of the GTPase-activating proteins. Its main 
physiological function is inactivation of energized ras oncogene. NF1 mutation extinguish a 
gene function and leads to aberrant ras activity. NF1 gene belongs to the family of tumor 
suppressor genes and neurofibromatosis type 1 is thought to be a hereditary malignancy 
syndrome, which is highly influenced by complex action of other genes, required in signal 
transmission processing. In human diseases predisposing to cancer, cells usually carry 
heterozygous germline, what means inherited, mutations in growth regulator genes that are 
essential for organized cell growth and differentiation. Affected individuals, such as Nf-1 
patients, are at significant risk for development of benign or malignant tumors early in life. 
In case of Nf-1, the most distinguished types of neoplasia are tumors arising from peripheral 
and optic nerves sheath (Schwann cells), usually benign neurofibroma and optic nerve 
glioma or seldom, malignant peripheral nerve sheath tumor [MPNST]. MPNST usually 
growths as a result of malignant transformation of plexiform neurofibroma [PNF], a specific, 
clinically distinguished type of neurofibroma. The risk of transformation of PNF into 
MPNST is not higher than 10%, and have been finally evaluated in recent clinical trials 
(Upadhyaya, 2011). The overall risk of cancer development in Nf-1 patients surpass the 
healthy general population risk by 2.7 times (Walker et al., 2006). The risk of malignancy is 
higher in those patients because inherited nature of the first mutation released the entire 
process, and in consequence, only one additional acquire genetic alteration, resulted in loss 
of the wild allele of affected gene, is further necessary to facilitate tumorigenesis. In healthy 
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individual both mutations must be acquire in intact alleles, so the chance for that is much 
lower. Cells that have lost both copies of the tumor suppressor gene have a growth 
advantage over so called wild cells. In a susceptible environment, this ‘second hit’ may 
result in tumor formation (Larizza et al., 2009; Upadhyaya, 2011). This helps to explain the 
development of neurofibromas and other malignancies occurring in Nf-1 patients, but 
currently does not fully explain the role of neurofibromin on the development of other 
ailments, and osseous abnormalities in particular. However the precise role of 
neurofibromin is not yet fully elucidated, although neurofibromin deficiency causes 
multiple clinical effects, suggesting that this gene product has diverse functions in a variety 
of tissues. Distorted process is responsible not only for tumorigenesis, but also for memory 
processing (intellectual disability) and bone remodeling (typical bone deformity seen in Nf-1 
patients) (Radtke et al., 2007). 
Phenotype expression of NF1 gene mutation is extremely variable, so even individuals from 
one family with identical germline mutation may have dramatically different clinical 
manifestations. Observed complexity and the diversity of constitutional NF1 mutations 
occurring in Nf-1 patients will continue to make genotype-phenotype correlation almost 
impossible. Clinical variability of Nf-1 results most probably from a combination of founder 
mutation effect of NF1 gene influenced by further action of other genes engaged in signal 
transduction, as well as other genetic, non-genetic, and stochastic factors (Jouhilahti et al., 
2011). Till now more than 500 different mutations of the NF1 gene have been identified, and 
most of them are unique to a particular family. Different, mostly loss-of-function mutations, 
have been observed repeatedly, but none has been found in more than a few percent of 
studied families (Radtke et al., 2007). In consequence, there are not so called hot spots 
sequences manifest along the entire gene length, what significantly complicated not only 
molecular testing but genetic counseling as well. Till now, only two clear correlations have 
been observed between particular mutant NF1 alleles and consistent clinical phenotypes. In 
one, the whole NF1 gene deletion is associated with more prominent presentation of the 
disease (Mensink et al., 2006). In another, characterized by 3-bp in-frame deletion of exon 17 
(c.2970-2972 delAAT), the typical pigmentary features, but no cutaneous or surface plexiform 
neurofibromas, exist (Upadhyaya et al., 2007). Data concerning NF1 mutation have 
accumulated slowly owing to the variability of the mutation types and the size and complexity 
of the gene, belongs to the longest in human genome. This also reflects the lack of a simple, 
inexpensive, highly accurate DNA-based test for Nf-1 at present (Radtke et al., 2007). 
Currently no treatments dedicated specifically to Nf-1 patients exist. Because of the 
increased risk of cancer and multiorgan involvement, Nf-1 patients required extensive 
medical surveillance, provided on the regular bases by the specific, highly specialized Nf-1 
clinics (Karwacki & Wozniak, 2006). It obey a comprehensive standards, comprises of 
regular physical examination by a Nf-1 specialist, regular blood pressure and 
ophthalmologic monitoring, anthropometric and developmental assessment of children and 
periodical imaging, warrants follow-up of clinically suspected intracranial and other 
internal tumors, done by USG and/or MR imaging. CT scans are hardly recommended in 
NF-1 patients, but children in particular, as the imaging exerts the risk of irradiation and is 
of limited diagnostic value, especially in visualization of Nf-1 brain specific lesions, called 
undifferentiated bright objects [UBO](DeBella et al., 2000a). According to specific ailment, 
patients are referred by Nf-1 clinic to other specialists as well. 
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The skeletal manifestations of a disease itself and the post-surgical bony complications 
occurred in Nf-1 patients, are common and have a prominent place in the orthopedic 
literature. The orthopedic complications of Nf-1, which usually appear early, include spinal 
deformities such as dystrophic scoliosis and kyphoscoliosis, congenital bowing and 
pseudoarthrosis of the tibia and the forearm, overgrowth phenomenon of the extremity, and 
soft tissue tumors, both benign and malignant (Crawford & Schorry, 1999, 2006). 
2. Primary and secondary bone abnormalities in neurofibromatosis type 1 
Although phenotype of Nf-1 patients is well described, the osseous manifestations are rarely 
emphasized in the clinical and genetic discussions concerning the diseases. In fact, one of the 
seventh diagnostic NIH criterion represents a distinctive osseous defect. Nf-1 is classically 
considers as a neurocutaneous disorder and clinical features of Nf-1 are classically thought of 
as neural crest in origin, but currently it is well accepted that mesodermally-derived 
abnormalities coexist as well. Restricted knowledge concerning the pathophysiology of Nf-1 
skeletal abnormalities reflects the limited therapeutic modalities. Nf-1 is characterized by a 
multifaceted, polysystemic pathology. Among the other, bone involvement is representative 
for the majority of patients with Nf-1. The presentation of an ailment differs from patient to 
patient, but sometimes is extremely severe and appear from the birth or become evident either 
early in the childhood or further on and will accentuate with age. A number of skeletal 
involvements are highly morbid with a natural history distinct from that of the general 
population. A large proportion of patients with Nf-1 display primary skeletal involvement, 
including scoliosis and pseudoarthrosis, which are compounded by osteoporosis and poor 
bone healing (Crawford & Schorry, 1999). In considerable proportion of patients, these bone 
lesions can result in significant morbidity. The natural history and pathogenesis of the skeletal 
abnormalities, resulted from alter NF1 gene function, are poorly understood. Consequently, 
therapeutic options for these ailments are currently limited. Corrective orthopedic intervention 
quite often fails necessitating multiple revision surgeries followed by prolonged recovery 
periods (Crawford & Schorry, 2006). 
Besides true dysplasia of bone, some of the skeletal changes observed in these patients are 
secondary to a tumor, compressing the bone through expansive growth, or its metastases. 
The most frequently, such tumors are plexiform neurofibromas, and rarely other 
malignancies occurred in Nf-1 more frequently than in general population, such as soft 
tissue sarcomas, notably rhabdomyosarcoma, and especially, malignant peripheral nerve 
sheath tumor [MPNST]. These tumors infiltrate easily in surrounding tissue, eroding the 
neighborhood bone, and frequently give rise to metastases, mostly to bones. Malignant 
peripheral nerve sheath tumor is an uncommon soft-tissue sarcoma [STS] that occurs at a 
higher incidence in patients with prior radiation exposure and Nf-1. MPNST resulted almost 
exclusively from the malignant transformation of PMF. It is assessed that every Nf-1 patient 
presenting PMF has a life time risk of 8 to 13% to develop a MPNST out of a pre-existing 
benign plexiform neurofibroma. In comparison to intragenic mutation, in patients with a 
NF1 microdeletion (5% of Nf-1 patients) this risk is twice as high. That risk is even greater in 
patients, in whom PMFs were incorporated into the field of therapeutic radiotherapy 
performed as an component of complex oncological treatment. Irradiation is linked with 
much higher risk of such a transformation, and in some STS therapeutic protocols 
introduced to the clinic by oncological treatment groups is either contraindicated or 
introduced with caution, when offered to children with Nf-1. Most of MPNST, especially 
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arising in Nf-1 patients, are considered high-grade sarcomas with the tendency to recur as 
well as to metastasize, typically to the lungs. It belongs to a group of malignancies of 
particularly worse prognosis and due to its rarity, there is a paucity of data concerning 
chemotherapy response of MPNST. 
As the overall understanding of bone growth, remodeling, and repair dependent on NF1 
gene function is critical to development of possible therapeutic interventions, in order to 
ensure continued collaboration and advancement toward better clinical management as well 
as effective drug therapies for Nf-1 related primary skeletal ailments, an International Nf-1 
Bone Abnormalities Consortium have been convened in February 2008. The main goal of 
this Consortium is to identify barriers that might be impeding progression to future clinical 
trials for Nf-1 skeletal abnormalities and to highlights priorities for future research, based on 
animal model of Nf-1 related bone disease (Elefteriou et al., 2009).  
2.1 Skeletal abnormalities in humans: Clinical presentation, diagnosis, complications 
The Nf-1 skeletal phenotypes might be either generalized or focal. Manifestation of 
generalized skeletal abnormalities, mostly osteopenia or osteoporosis and short stature, are 
common, but of mild clinical implications. Focal lesions, such as tibial dysplasia, short angle 
scoliosis, and sphenoid wing dysplasia, are less common, but usually cause significant 
morbidity. 
 
Skeletal Deformities: 
- Short stature 
- Macrocephaly 
- Sphenoid wing dysplasia  
- Cervical spine disorders 
- Scoliosis 
- short-angle dystrophic 
- idiopathic non-dystrophic 
- Spondylolisthesis 
- Kyphoscoliosis  
- Abnormalities of the rib cage and/or rib fusion 
- Long bone dysplasia 
- Osteosclerosis 
- Congenital bone bowing 
- Pseudoarthrosis 
- Genu varum/valgum 
- Absence of the patella 
- Subperiosteal bone proliferation 
- Partial overgrowth of an extremity  
- Syndactyly 
- Intra osseous-cysts and lytic bone lesions 
Bone Metabolism Disorders:  
- Osteopenia and frank osteoporosis 
- Hypophosphatemic rickets 
- Impaired bone healing 
Table 2. Frequent manifestations of osseous abnormalities in patients suffering from Nf-1 
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2.1.1 Focal lesions: Spinal and chest wall deformations  
Spinal deformities frequently occur in individuals with Nf-1. These changes result from intra 
or perispinal pathology, such as tumors, or either meningoceles or dural ectasia. However, the 
deformities may be also present in persons with entirely normal intraspinal contents. In such 
patients, primary bone dysplasia accounts for the dystrophic vertebral changes.  
The most frequent is scoliosis, and the most devastating form – kyphoscoliosis of 
progressive course regardless the intensive physiotherapy. In various series of Nf-1 patients 
reported in the literature, frequency of scoliosis is assumed for 10 to 33% (Crawford & 
Herrera-Soto, 2007; Wang & Liu, 2010). Vice versa, in general population, Nf-1 could be 
confirm in app. 2% of children suffering from scoliosis (Vitale et al., 2002). Orthopedic 
surgeons distinguished two types of spinal curvature disturbances in children with Nf-1: 
dystrophic and non-dystrophic. The cause of spinal deformity in Nf-1 is still a matter of 
debate, but some have suggested that it is secondary to endocrine disturbances observed in 
these patients, mesodermal dysplasia probably resulted from NF1 mutations, and 
osteomalacia, caused by a localized neurofibromatous tumor eroding and infiltrating 
adjacent bone. 
The dystrophic scoliosis, usually associated with paravertebral neurofibromas, has a 
progressive nature and is associated with vertebral scalloping and wedging. Almost always 
develops before 10th year of life (Crawford & Herrera-Soto, 2007). Dystrophic scoliosis is 
often early onsetting, the shortsegmented, sharply angulated type of this ailment that 
includes fewer than 6 spinal segments. It has a tendency to progress to a severe deformity. 
The term dystrophic is usually used to describe a dysplastic vertebrae observed within 
scoliotic spine. Although there is no formal diagnostic criterion for such a form of scoliosis, 
Durrani et al. (2000) described nine specific radiographic features associated with dystrophic 
scoliosis (Tabl. 3). 
  
1. Scalloping of the posterior vertebral margins 
2. Severe rotation of the apical vertebra 
3. Widening of the spinal canal 
4. Enlargement of the neural foramina 
5. Defective pedicles 
6. A paraspinal mass 
7. Spindling of the transverse process 
8. Rotation of the ribs (the ribs resemble twisted ribbons) 
Table 3. The radiologic appearance of the dystrophic scoliosis (Durrani et al., 2000) 
Distinctive radiographic features of dystrophic scoliosis, usually presented in the 
preadolescent child, include a short-segment sharply angulated curve (involving four to six 
vertebrae), scalloping of vertebral margins, vertebral wedging, spinal canal widening, 
defective pedicles, and rib-penciling (Crawford et al., 2007). It is potentially debilitating and 
may rapidly progress to neurological impairment. This kind of scoliosis is frequently 
associated with paraspinal or other internal neurofibromas adjacent to the vertebrae, which 
could be seen in app. 70% of Nf-1 patients’ MRI  (Khong et al., 2003; Ramachandran et al., 
2004). The complication of NFMs, or much frequently, PNFs penetrating into vertebral canal 
is dural ectasia, defined as widening of the dural sac surrounding the spinal cord, which 
might be seen in these patients (Khong et al., 2003; Schonauer et al., 2000; Tubbs and Oakes, 
www.intechopen.com
The Skeleton Abnormalities in Patients with  
Neurofibromatosis Type 1: Important Consequences of Abnormal Gene Function  
 
329 
2002). However, dural ectasia may be a primary mesodermal dysplasia of the meninges as 
well (Casselman and Mandell, 1979). The vertebral column can further displace or erode, 
causing rib dislocation into the spinal canal, resulting in spinal cord injury. Weakening of 
spinal natural stabilizers, such as facets, pedicles, and ligaments, usually distorted in Nf-1, 
may lead to kyphosis. Kyphoscoliosis and humpback is a severe complication of advanced 
dystrophic scoliosis and finally can lead to cardiorespiratory insufficiency and failure. In 
this point, the best and well known touching description of Nf-1 patient’s suffering, given 
by Victor Hugo in “The Hunchback of Notre Dame”, is worth to be remembered. 
Dystrophic scoliosis in Nf-1 patients is particularly difficult to treat and necessitates early 
aggressive surgical stabilization very often. 
The other, milder form of scoliosis occurring in Nf-1 children, is called non-dystrophic. It is 
diagnosed typically during adolescence and resembles idiopathic adolescent scoliosis in 
healthy population (Crawford & Herrera-Soto, 2007; Wang & Liu, 2010). This form usually 
involves 8-10 spinal segments. The deformity is most often convex to the right; however, 
this is not consistent. In rare instances, non-dystrophic scoliosis can progress to the 
dystrophic form.  
The presence of neurofibroma or abnormal pressure phenomena in and around the spinal 
canal neuraxis resulted in meningoceles, pseudomeningoceles, dural ectasia, and dumbbell 
lesions development.  
Kyphosis in individuals with Nf-1 might be distinguished by acute anteroposterior 
angulation. Severe deformity of vertebral bodies in Nf-1 might be confused even with 
congenital deformities. 
Chest wall deformities in patients with Nf-1 are observed even more frequently than 
scoliosis, and are thought to be present in as many as 50% of patients (Riccardi, 2010). The 
relationship between chest wall deformities and scoliosis is not clear, but its existence 
exacerbates the course of dysplastic scoliosis in particular. It could happened, that chest wall 
deformities constitute the first clinical sign of tumor arising within the chest and quite often 
penetrating throughout the intervertebral foramina or dura mater. It resembles an hourglass 
shape, and is called spinal dumbbell tumor. This kind of growth is usually form by multiple 
tumors arose in the intradural and epidural spaces from one nerve root, occurring at the 
same time in different regions, such as the paravertebral, epidural and intradural spaces. 
Histopathological diagnosis is usually plexiform neurofibroma, but it still comprises the risk 
of malignant transformation into MPNST.  
2.1.2 Focal lesions: Head and neck region  
Increased head circumference is frequently observed in patients with Nf-1, and macrocephaly 
(head circumference >2 SD above the mean) occurs in about one-fourth of patients (Szudek et 
al., 2000). It is thought to be the consequence of  brain enlargement (Greenwood et al., 2005). It 
is still not clear whether the skull growth contributes to macrocephaly. Contrariously, the 
association between macrocephaly and learning disabilities or underlying structural brain 
abnormalities has never been proof (Gutmann at al., 1997). 
Sphenoid Wing Dysplasia Cranial defects attributed to the clinical pathology in Nf-1 with 
relatively lower frequency (eg. 11% had a dysplastic sphenoid wing in an observational 
study of Friedman and Birch (1997)). Sphenoid dysplasia usually is asymptomatic but 
occasionally can be associated with herniation through the bony defect. It is still under 
debate whether these type of changes reveal a primary bone dysplasia related to NF1 
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mutation, or occur as secondary response of bone to the adjacent soft tissue abnormality. 
Most cranial defects are associated with plexiform neurofibromas of the eyelid or temporal 
region induced ipsilateral infiltration and decalcification of cranial bones adjacent to tumors 
(Jacquemin et al., 2002, 2003). Other lesions, including arachnoid cysts, dural ectasia, or 
buphthalmos, usually associate sphenoid wing defects. The suggestion of a bone cell-
autonomous defect, accounted for the dysplastic sphenoid wing, is based on two 
meaningful observations: (1) Nf-1 sphenoid wing lesions have been associated with tibial 
and vertebral dysplasia (Alwan et al., 2007), and (2) formation of this skull structure 
proceeds through endochondral bone formation, which is defective in Nf-1 (Kolanczyk et 
al., 2007). Regardless the cause, a congenital malformation or secondary bony defect, the 
sphenoid wing dysplasia is not currently a primary target for therapeutic prevention. 
Nevertheless, it is imperious necessity to apply sensitive imaging techniques to screen 
patients with sphenoid wing dysplasia for adjacent tumors, which may be amenable to 
therapy (Jacquemin, 2002, 2003). 
Increased caries and early primary tooth eruption as well as periapical cemental dysplasia 
have been quite often reported in patients with Nf-1 (Lammert et al., 2007; Tucker et al., 
2007; Visnapuu et al., 2007). Dental abnormalities in Nf-1 patients still require more 
attention, yet everyday practice pointed  unnecessary dental procedures performed in these 
patients, for instance when periapical cemental dysplasia is confused with chronic 
inflammation on radiographic analysis and precipitate dental surgery. 
Cervical spine abnormalities are due to cervical spine instability or intraspinal pathology, 
caused mostly by benign tumor. These occur much more frequently when a scoliosis or 
kyphoscoliosis is present in the thoracolumbar region, but could be omitted as the 
examiner's attention is focused on the more obvious deformity. Severe cervical kyphosis is 
the most common abnormality, which itself is highly suggestive for Nf-1 diagnosis. Patients 
usually had either limited motion or pain in the neck, which were probably attributed to 
cervical instability. The numerous, minor to major neurologic deficits, such as paraplegia, 
are present. 
2.1.3 Focal lesions: Long bones and extremities  
Long bone dysplasia appears in a small percentage (3–4%) of patients with Nf-1 in clinic-
based series (Friedman & Birch, 1997) and tibia is involved most often among other long 
bones, which can be affected sparsely. Infant with such an ailment usually presents with 
unilateral anterolateral bowing of the lower leg, notably tibial, although a child may be born 
with fracture and/or pseudarthrosis as well, or develop these shortly after birth. The 
deformity may appear before other protean manifestations of Nf-1, such as café-au-lait 
spots. The tibial bowing is usually evident within the first year of life, with a fracture not 
uncommonly occurring by age of 2-2.5 year. The tibial bowing associated with Nf-1 is 
always anterolateral. Affected bone is subject to pathologic fracture usually before age 3 
years, often with minimal trauma. Subsequent healing may not occur normally, leading to 
consecutive non-union and pseudoarthrosis, sometimes requiring even amputation of 
affected extremity. As confirm histologically, the fibrous pseudarthrosis tissue seen at the 
fracture site is not a neurofibroma, but a fibrous overgrowth of unspecified cell origin. The 
ipsilateral fibula is often involved in association with tibial pseudoarthrosis and focal 
dysplasia of the ulna, radius, scapula, or vertebra may occur as well. The anterolateral 
bowing characterized patients with Nf-1 should be distinguished from the bilateral 
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physiological bowing, exemplary common in children as they begin to walk or from the 
other type pathology.  
Various radiographic classification systems for tibia bowing have been proposed, but they are 
still not rigorous and  several subtypes represent rather changes over time, than the real 
variety. Nevertheless, tibial bowing in Nf-1 patients prior to fracture represents in radiograph 
a cortical thickening and medullary canal narrowing at the apex of the convexity, typically 
near the junction of the middle and distal thirds of the tibia (Stevenson et al., 2007).  
In general, every bone of whatever kind and at any localization may usually be affected by 
the adjacent tumors as well, with all the consequences resemble the ones described above. 
2.1.4 Generalized skeletal abnormalities 
Although focal skeletal abnormalities, such as dystrophic scoliosis or tibial pseudoarthrosis 
and the like, can be severely disabling, they are uncommon among individuals with Nf-1. In 
contrary, generalized skeletal abnormalities are less severe but much more frequent in these 
patients. The osseous dysplasia result from disturbed bone growth, perhaps secondary to a 
mineralization disturbance. Findings such as decreased bone mineral density (BMD) and 
short stature reflect a generalized alteration of bone. The Nf-1 patients tend to be below 
average in height for age (below -2SD), although heights  less than -3SD below the mean is 
seen hardly ever. Decreased BMD in both sexes at an early age has been reported in up to 
50% of individuals with Nf-1. Reduced BMD in Nf-1 patients was initially recognized by 
Illes et al. (2001).  
The exact pathogenesis of these bony changes is not understood, but patients with Nf-1 
present lower than expected serum 25-hydroxyvitamin D (25OHD) concentrations, elevated 
serum parathyroid hormone concentration, and evidence of increased bone resorption. 
Defects in vitamin D metabolism, osteoclastogenesis or bone cell response to systemic 
signals regulating bone remodeling are likely involved. An inadequate increase in bone 
remodeling is also indirectly confirm by both bone histomorphometry and changes in 
circulating bone markers (Stevenson et al., 2008; Seitz et al., 2010). However, an increased 
incidence of fractures has not been firmly established. Still, generalized osteopenia and 
frank osteoporosis are more common than expected in patients with Nf-1. The results of one 
of the biggest series, in which Nf-1 children became the subject of multivariant analysis,  
indicate that the mean lumbar and whole body BMD z-scores were in the range of 
osteopenia and osteoporosis in 48% and 25% of subjects, respectively. BMD was reduced at 
multiple bone sites, while the lumbar spine being more severely affected (Brunetti-Pierri et 
al., 2008). A tumor inductive role has also been suggested (Ben-Baruch et al., 1994). 
Several case reports from Nf-1 patients have identified histologically proven osteomalacia, 
which might be associated with hypophosphatemia due to renal phosphate wasting (Abdel-
Wanis & Kawahara, 2002). Although the concentration of baseline vitamin D were in the 
normal range in these patients, researchers further found that the osteomalacia can be 
reversed independently of phosphate supplementation with oral treatment of 1-alpha-(OH)-
vitamin D3 (Konishi et al., 1991). Moreover, a recently published comparative study 
reported that 25OHD serum concentration were about twofold lower in the Nf-1 patients 
than in healthy population and were inversely correlated with the number of neurofibromas 
(Lammert et al., 2006). The exact underlying mechanism of vitamin D deficiency in Nf-1 
patients still remains unclear as well as the value of vitamin D supplementation for the 
treatment of the patients is still poorly understood. 
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Selected genetic disease populations, including Nf-1, display increased risks for 
osteoporosis, which is an emerging complication of utmost importance. Early diagnosis in 
the pediatric population is essential, since the highest contribution to peak bone mass is 
attained in the first three decades. Osteopenia or decreased bone mass accrual in the 
pediatric period can lead to frank osteoporosis and fractures in adulthood in the general 
population, as peak bone density is generally reached by late adolescence. Emerging 
evidence shows that vitamin D deficiency combined with a higher than normal bone 
turnover contributes to decreased bone mineral density in patients with Nf-1. The results of 
currently published studies suggest that the population of Nf-1 patient is at an increased 
risk for the development of clinical complications related to osteoporosis.  
Seldom but yet published data revealed that significantly lower blood concentration of 
osteocalcin was observed in Nf-1 patients with, in comparison with patients without, 
skeletal abnormalities. Osteocalcin is secreted by osteoblasts, plays a role in mineralization 
and calcium ion homeostasis and its level reflects the rate of bone formation. Reduced blood 
concentration of osteocalcin in Nf-1 patients with skeletal deformity may indicate defect in 
osteoblasts functioning. Other biochemical markers of bone turnover usually do not exhibit 
any difference between these groups (Duman et al., 2008). When compared to healthy 
subjects, in  Nf-1 patients BMD of the lumbar spine and femoral neck is significantly 
decreased. The same significant decrease apply to pubertal patients when compared to 
pubertal controls and in prepubertal patients when compared to prepubertal controls. The 
decrease in BMD is still more pronounced in Nf-1 patients with severe scoliosis, than those 
without spinal deformities. Duman et al. (2008) suggests that relevant predictors of skeletal 
abnormalities among Nf-1 patients are bone formation markers (exclusively osteocalcin) 
rather than imaging (conventional radiography, CT, MRI or quantitative ultrasonometry of 
the calcaneal bone) and densitometry techniques, especially dual-energy X-ray 
absorptiometry (DXA). In opposite to this report, the other published data suggest that both 
DXA and quantitative ultrasonometry of the calcaneal or other bones may prove useful to 
identify individuals with NF1 who are at risk for clinical osseous complications. These 
techniques and the logistics, introduced into pediatric practice quite recently, may also be 
appropriate for monitoring of therapeutic trials concerning skeletal ailments in Nf-1 
children. However, many significant heterogeneities among the reports in the literature, 
such as patient groups (ages, variability of skeletal involvements, etc.) and methods (BMD 
assaying, comparison criteria such as T-score, Z-score, their cutoff points, etc.) make the 
comparisons amongst the studies very difficult. The densitometric criterion commonly used 
as a predictor of fracture risk for osteoporotic adults, called T-scores, derived from reference 
populations of young-adult women. While useful for evaluation of fracture risk in adults, 
but especially in postmenopausal women, is not applicable to the diagnosis of osteoporosis 
in children. In this age period the evaluation of osteoporotic risk of fracture is much more 
difficult. Densitometric data in children must be compared with age-matched control 
populations (z-scores). Currently, it is generally accepted that z-scores below −1.5 indicate 
low bone mass or osteopenia, and that osteoporosis is suspected strongly with z-scores 
below −2, especially followed by the episodes of fracturing. According to Writing Group for 
the ISCD Position Development Conference, z-score less than −2 define low bone density in 
children (2004). 
According to unique published papers, children with Nf-1 had also statistically significant 
decreases in muscle mass compared to healthy controls regardless the presence or not of 
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clinically proven osseous abnormalities (Stevenson et al., 2005). Muscle mass is important in 
the development of bone strength, as voluntary muscle forces (the largest physiological 
load) impact skeletal response. Combinations of extrinsic forces including decreased muscle 
mass could compromise potentially abnormal osseous matrix as well.  
It is well known that NF1 gene is widely expressed in chondrocytes, osteoblasts, osteoclast, 
and osteocytes (Kuorilehto et al., 2004). Kuorilehto et al. (2004) reported as well that 
neurofibromin is expressed in growing cartilage in areas where proliferation has ceased and 
the chondrocytes are undergoing differentiation, and in periostealosteoblasts of embryonic 
and mature mice and rats. However, mechanism of various skeletal deformities and bone 
metabolism defects in  Nf-1 patients are not clearly understood. Experimental work done on 
animal models suggest that patients with Nf-1 suffers from a bone formation defect rather 
than bone resorption.  
2.1.5 Other skeletal manifestations of neurofibromatosis type 1 
Individuals with Nf-1 tend to be shorter than expected for their families (Szudek et al., 2000; 
Virdis et al., 2003), with 20–30% of adults with NF1 estimated to have a height below the 3rd 
centile. Growth velocity in these individuals is typically normal or near normal before 
puberty, then declines. Short stature in patients with NF1 is usually proportional. Scoliosis, 
growth hormone deficiency, and other Nf-1 related complications can contribute to short 
stature, but the cause of this in most patients with Nf-1 is unknown. 
Bony abnormalities may be clinically silent, with radiographic evidence of long bone 
intramedullary fibrosis, cortical thinning, or vertebral dural ectasias often found incidentally.  
Among the other bone abnormalities observed Nf-1 patients rarely, but with frequency a bit 
higher than in general populations, are cystic osseous lesions. They are usually identified 
incidentally during ongoing process of repeated imaging, reflecting the international 
recommendations. Found during radiographic knee exam, these cystic lesions are 
occasionally seen in the absence of tumors or long bone dysplasia (Colby & Saul, 2003; Lee 
& Cho, 2006). The lesions rarely fracture or show progressive deformity, and biopsy 
generally shows non-ossifying fibroma bone tumors. The association of multiple non-
ossifying fibromas with cafe au lait skin patches are the fundamental signs of Jaffee-
Campanacci syndrome (JCS) (Campanacci et al., 1983). The long bones affected more often 
are the femur, the humerus, and the tibia as well as the bones of the jaw. Other bones can be 
involved less frequently, especially the pelvis, the fibula, the radius, and the ulna. The 
lesions may be large enough to cause pathological fracture of the involved bone. Recent 
findings suggest that JCS may be a form of Nf-1 (Colby & Saul, 2003). 
2.2 Pathophysiology of skeletal abnormalities in neurofibromatosis type 1: 
Experience from transgenic mouse models 
Studies assessing the role of NF1 gene not only in tumor formation and development, but 
also in pathogenesis of other multiple abnormalities, are to be a matter of numerous 
experimental work, which cannot be apply neither on living individuals, nor cell lines. 
These restrictions led to the development of transgenic mouse models allowing 
determination of the role of NF1 gene and its product in affected systems and facilitate 
preclinical studies. Unfortunately, mice’s embryos with inactivated both NF1 alleles exhibit 
severe neural closure defect, namely exencephaly, and cardiovascular abnormalities 
including structural malformations of the outflow tract of the heart and enlarged 
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endocardial cushions. These NF1-deficient embryos die between embryonic days 12.5 and 
13.5, presumably due to the cardiac vessel defect. In contrast to completely defective 
organism, inactivation of only one allele of NF1 gene locally, in the neural crest only, does not 
cause cardiac defects but results in tumors of neural crest origin, resembling those seen in Nf-1 
patients. Following this early experiments the another models of an experimental animal has 
been developed to determine the role of NF1 in bone cells and resolve difficulties in 
understanding the human pathophysiology of Nf-1 skeletal defects (Kolanczyk, 2007, 2008). 
It has been well known that neurofibromin is a cytoplasmic protein that is predominantly 
expressed in neurons, Schwann cells, oligodendrocytes, astrocytes, and leukocytes. Due to 
early studies based on transgenic animal models of skeletal defective mice it is obvious 
currently that NF1-mRNA and neurofibromin are expressed in mouse bone and cartilage 
during development and adulthood (Kuorilehto et al., 2004), and more specifically in 
mesenchymal stem cells, chondrocytes, osteoblasts (Elefteriou et al., 2006; Kolanczyk et al., 
2007), and osteoclasts (Yang et al., 2006a). Kuorilehto et al. (2004) reported the expression of 
neurofibromin in growth plate, periosteum, and tracebular bone of mice, and the expression 
in growth plate was mainly located in chondrocytes of the hypertrophic layer. Yu et al 
(2005) showed that upon the activation of ras signals, NF1+/- murine osteoprogenitor cells 
show increased proliferation and premature apoptosis; the osteoprogenitor cells also exhibit 
a lower rate of differentiation to osteoblasts. He considered neurofibromin and its role as ras 
signal regulator to be necessary for osteoblast function. Kolanczyk et al (2007) found that 
osteoblasts from NF1Prx1(NF1+/-) mice show increased proliferation and decreased 
abilities to differentiate and mineralize, whereas chondrocytes demonstrate a lower 
proliferation rate and defective differentiation. These results indicate that NF1 has multiple 
roles in skeletal development including joint formation, growth plate function, osteoblast 
differentiation, and control of vessel growth, and proved that NF1 is an important regulator 
of development and growth of the skeleton. The pattern of expression suggests that NF1-
related skeletal abnormalities stem in part from primary osseous defects caused by bone 
cellular dysfunctions related to generalized NF1 heterozygosity, and/or to NF1 loss of 
function in specific bone cell types.  
Investigations of affected skeletal tissue in tibial pseudarthrosis model created by 
inactivation of one of NF1 alleles during early mouse limb development, confirm that 
further mutation of the second NF1 allele, thus the homozygous loss of NF1 function, was 
detrimental for normal bone development. Thus, like in NF1-mediated tumorigenicity, a loss 
of both NF1 alleles is likely to be required to cause the skeletal abnormality phenotype. 
Available mouse models recapitulate some, but not all, of the bone abnormalities in patients 
with Nf-1. Mouse data helped clarify that NF1 haploinsufficiency is likely related to the 
generalized Nf-1 bone remodeling defects, whereas total loss of NF1 function is likely 
related to the focal dysplastic events. Identifying neurofibromin cellular functions, target 
genes and downstream signaling pathways remains a priority to understand the etiology of 
the Nf-1 skeletal manifestations.  
3. Present day and future treatment of skeletal dysplasia in 
neurofibromatosis type 1 
Consensus guidelines for the treatment of the specific orthopedic manifestations in patients 
with Nf-1 do not exist and clinical management practices for each Nf-1 skeletal abnormality 
varied considerably.  
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At present, there are either no clinical trials to support the use of osteoporotic drugs in a 
population of Nf-1 patients or treatment guidelines. Thus, conservative therapy to promote 
bone health, such as treatment with calcium and vitamin D, and weight-bearing exercise 
forms the first line of therapy in children with Nf-1 and low bone mass. Correction of 
measured deficiencies in hormones (vitamin D, thyroid, estrogen, etc.) that are known to 
regulate skeletal growth and maturation is inevitable. Judicious vitamin D supplementation 
may prove beneficial for patients with Nf-1 who have vitamin D deficiency or evidence of 
osteopenia. Similarly, until further information is obtained, treatment of osteoporosis in 
adults with Nf-1 follow the recommendations developed for general population. Because 
low serum 25-OH-D and osteomalacia has been reported in patients with Nf-1 and low bone 
mass, osteoporotic adult patients over age 50 years should take supplemental 1,200 mg 
calcium and 800–1,000 IU vitamin D per day, and reduce clinical risk factors by regular 
weight bearing and muscle strengthening exercises and avoidance of smoking and excessive 
alcohol. Selection of approved anabolic or anti-resorptive drugs to prevent or treat 
osteoporotic fractures should follow the standard practice with exception of children. 
Children should be treated as well, as soon as fracture complicates the 
osteopenic/osteoporotic bone dysplasia (Elefteriou, 2009). Unfortunately, anabolic 
substances available currently upon two forms of parathyroid hormone pose the increased 
risk of osteosarcoma development, proven in rats, and are contraindicated in children 
(Tashjian & Gagel, 2006). Bisphosphonates and monoclonal antibodies that target 
osteoclasts, belonging to anti-resorptive drugs, have been used to reduce osteoporotic 
fractures in adults, but their effect on BMD and fracture risk in children with Nf-1 is 
unknown. Clinical trials are necessary to determine which of currently available therapies 
are most effective to treat patients with Nf-1 and reduces BMD, but especially frank 
osteoporosis. 
In patients with Nf-1, the morbidity associated with either dystrophic scoliosis or tibial 
dysplasia is much greater than that of osteopenia and osteoporosis or even non-dystrophic 
scoliosis. This helps define priorities for current and future trials. Some of the ailments, 
particularly dystrophic scoliosis or tibial bowing, can lead to clinically significant 
consequences if neglected.  
Children with  dystrophic scoliosis require the extensive medical attention. In children who 
do not complete skeletal maturation, typically presented dystrophic form of scoliosis, 
bracing is routinely used when the spine curvature exceeded 25 up to 45 degrees. While the 
curvature progresses to more than 45 degrees before maturity or 55 degrees after maturity, 
surgery is commonly employed. Unique management approach due to progression is 
necessary in skeletally immature patients with dystrophic scoliosis in whom a curvature 
exciding 30 degrees. Exclusion of paravertebral tumors and dystrophic changes required 
MR or, less sensitive, CT imagings, as those finding may be missed on plain radiographs. 
Regarding possible complications of surgery, careful presurgical assessment is critical, as the 
lamina may be thin, the canal affected by dural ectasia or intraspinal tumors, and a rib may 
have displaced into the spinal canal, all of which express an increased risk of poor post-
surgical outcome. Variables such as age, gender, associated neurofibromas, location and 
degree of the curve, and associated radiographic dystrophic features make the operation 
design difficult. Surgical treatment with fusion and growing rods is complex. Occasionally, 
intraspinal elements may directly compromise the cord when instrumentation and 
stabilization are attempted, or they may cause erosive changes in the bone, preventing 
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primary fusion. The local condition may exclude the possibility of radical excision of tumor 
not infrequently, additionally worsen the postsurgical outcome. A lack of animal models of 
dystrophic scoliosis and consequently poor understanding of the natural history of this 
ailment, additionally hinder progress. As the pathogenesis of Nf-1 dystrophic scoliosis is 
still poorly understood, there are no clear pharmacologic adjunctive options. It is postulated, 
that prospective studies to determine the relationship of spinal neurofibromas in patients 
with dystrophic scoliosis may help to determine if early treatment of spinal tumors could 
prevent dystrophic scoliosis. Currently there is no effective treatment for Nf-1 related dural 
ectasia. If microfractures and vertebral wedging with subsequent development of scoliosis is 
diagnosed, then pharmacologic agents to increase vertebral strength may be appropriate 
(Elefteriou, 2009). 
The dumbbell tumors, most of which are located unilaterally in the spinal canal and 
paravertebral space, are excised through a hemilaminectomy and a facetectomy, because 
these techniques provide  large space for tumors excision. In addition, the spinal stability 
can be reconstructed by Rogers wiring and contralateral facet fusion, because the 
hemilaminectomy and facetectomy can minimize damage to spinal stability by leaving the 
spinous process, supra- and intraspinous ligaments, and contralateral facet joint. 
Some dermal and most often internal plexiform neurofibromas, generally larger, more 
diffuse, and locally invasive to adjacent tissue and bone are seen in more than one fourth of 
patients with Nf-1 and can present a surgical or medical management conundrum. Besides 
pain, disfigurement, neurological and other clinical deficits complicated its growth, the 
wisdom of watchful waiting versus aggressive intervention is often debated (Wozniak & 
Karwacki, 2008). Complete resection of a PNF, radicalism of which is always controversial, 
without residual functional deficits is rarely possible, on the other hand, it must be 
remembered that app. 10% of them undergo malignant transformation. Thus debulking or 
partial resection of PNF may be undertaken not only for cosmetic purposes, but especially 
when progressive functional consequences are anticipated. 
Surgical treatment of the chest wall deformities is usually not required, and the ailment, as 
well as short but proportional stature and not prominent macrocephaly, are assumed as 
principally cosmetic.  
Sphenoid wing dysplasia, comprising a congenital malformation or a secondary bony 
defect, is not a primary target for therapeutic prevention. Although, it requires sensitive 
imaging techniques, particularly MRI, to screen patient for adjacent tumor, which may be 
amenable to therapy. 
The management of anterolateral bowing deformity, characteristic for Nf-1, is most 
frustrating. Unlike scoliosis, treatment of congenital pseudarthrosis of the tibia does not 
appear to be more successful when it is initiated early. Anecdotally, early surgical 
intervention in children with Nf-1 and tibial pseudarthrosis results in poorer outcomes 
compared to later surgical management. The Consortium orthopedists recommended 
routine bracing of the dysplastic long bone upon diagnosis of bowing and agreed that 
prophylactic surgery should be avoided (Elefteriou, 2009). So, the current standard for 
treatment of long bone bowing in children is bracing to prevent fracture. The majority of 
members of the Consortium advocated early bracing until the child achieves maturity and, 
in some cases, continued even into adulthood. Evaluations of brace type, duration of use, or 
long-term benefits have not been obvious. Treatment of long bone pseudarthrosis is often 
unsatisfactory and very often require multiple surgeries or ultimate amputation. It is general 
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belief that bracing after pathological fracture should continue, delaying surgery until mid-
childhood, in fifth - eight year of age at earliest. Among the surgical procedures the most 
often applied are resection of the pseudarthrotic region and bone bridging with fixation via 
intramedullary stabilization devices, or free vascularized fibular grafting (contralateral or 
ipsilateral), or external fixation (e.g., Ilizarov technique), either alone or in combination with 
transankle fixation. Residual angular deformity, ankle stiffness, limb length discrepancy, 
refracture, and chronic pain are amongst the most severe complications of long bone 
pseudarthrosis. Attempts must been made to promote bone healing, always impaired in 
children with Nf-1 affected bones. Thus, electrical stimulation, varying periods of 
postoperative immobilization, supplemental bone grafting, and more sophisticated 
techniques, such as application of bone morphogenetic proteins and monocytic progenitors 
stem cells are under the routine or experimental options. Summarizing, tibial dysplasia with 
pseudarthrosis is still challenging Nf-1 skeletal manifestation required further extensive 
elaboration, on both scientific and everyday practice fields (Elefteriou, 2009). 
Established transgenic mouse models of NF1 gene and its protein dysfunctions opens up 
new vistas for a better understanding of the natural history and the development of new 
therapies and long-term orthopedic management essential to improve patient care. Based on 
data from these models, a variety of cell types and signaling pathways are likely to be 
involved in Nf-1 patients with bone manifestations. Therefore, combination therapies, using 
both anabolic and anti-catabolic medications, will likely give optimal results. For example, 
use of locally applied biological mediators (e.g., bone morphogenetic protein) at the time of 
surgery in patients with pseudarthrosis is an attractive option in order to avoid 
complications of systemic administration of pharmacologic agents. Unfortunately, no mouse 
model, even closely resembles the human skeletal manifestations, is fully identical, despite 
similarities with the human condition, in part due to the limitations of the genetic 
manipulations. Nevertheless, NF1-deficient mice are currently the only and highly valuable 
project in preclinical testing of candidate therapies for Nf-1 skeletal defects. 
Various studies have been initiated until now in preclinical mouse models to assess the 
potential efficacy of selected drugs on bone formation, repair and remodeling. Even when 
they represent just an initial approach, the most promising demonstrated potential of 
bisphosphonates (such as zolendronic acid) and recombinant human bone morphogenetic 
proteins (rhBMPs), which induces bone and cartilage formation, for improved net bone 
production in an in vivo model of heterotopic bone formation (Schindeler et al., 2008, 
Schindeler et al., 2011). Bisphosphonates are currently approved for other applications, so 
they could transition rapidly to Nf-1 clinical trials. Kolanczyk et al. (2008) quite recently 
published data concerning lovastatin, which improves cortical bone injury healing defects 
observed in the NF1-deficient mice. The inhibition of Ras/Erk signaling by lovastatin and 
other statins in mouse model counteracts the Ras/Erk constitutive activation occurred in 
NF1-deficient osteoblasts (as in Schwann cells), and improves bone healing defects. His 
work established the base for future experiments aimed at the treatment of the focal Nf-1 
bone changes with local statin’s delivery (Weixi et al., 2010). 
4. Final remarks and conclusions for the future 
Although neurofibromatosis type 1 is associated with marked clinical variability, most 
affected children do well from the standpoint of their growth and development. Some 
features of Nf-1 are present at birth, and others are age related abnormalities of tissue 
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proliferation, which necessitate periodic monitoring to address ongoing health and 
developmental needs and to minimize the risk of serious medical complications. Among the 
most important and often debilitating are skeletal abnormalities. The skeleton is frequently 
affected in individuals with Nf-1, and some of these bone manifestations can result in 
significant morbidity and even profound invalidism. The natural history and pathogenesis 
of these skeletal abnormalities are still poorly understood and consequently therapeutic 
options for these manifestations are currently limited. Lately established transgenic mouse 
models as well as continuously developing new and improved imaging techniques warrants 
further achievements either in basic science concerning the complications of NF1 mutation 
or clinical availability of diagnostic tools. The ongoing investigational trials, both preclinical 
and clinical as well as observational, gather significant number of participants, strengthen 
patient's belief for future improved care and therapy potentially freed them from often 
burdensome complications of disease course.  
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